Last checked at 8 Dec 2022 07:06
ReNeuron Group plc
("ReNeuron" or the "Company")
Positive induced pluripotent stem cell data presented at industry conference
ReNeuron presents new data highlighting the advantages of its novel type of iPSCs including data
from the Company's collaboration with University College London
ReNeuron Group plc (AIM: RENE), a UK-based leader in stem cell derived exosomes technologies, announces that one of its lead scientists, Dr Steve Pells, yesterday presented new data on the advantages of its induced pluripotent stem cells (iPSCs) including data from the Company's collaboration with University College London (UCL), at a major industry conference on iPSC-Derived Cell Therapies.
Key highlights from the presentation entitled Conditionally Immortalised iPSCs: A New Approach to Off-the-Shelf Allogeneic iPSC-Derived Cell Therapies included:
· Data was presented on the benefits of ReNeuron's novel type of iPSCs, known as Conditionally Immortalised Induced Pluripotent Stem Cells (CI-iPSCs)
· CI-iPSCs can differentiate into any cell type found in the human body, however unlike classical iPSCs, the addition of the conditional immortalisation technology gives greater control of the growth and survival of the subsequent differentiated cells, making them easier to grow in large quantities, purify and bank
· Data was presented highlighting how the use of CI-iPSCs lead to the manufacture of stable Schwann cells for the treatment of peripheral nerve damage repair
· This feature of CI-iPSCs also provides the ideal pluripotent stem cell line for the development of "off the shelf" stem cell-based therapies with work ongoing at UCL
The presentation will be available shortly on the Company's website: https://www.reneuron.com/investors/presentations/
Dr Randolph Corteling, Chief Scientific Officer, commented: "The data presented yesterday really highlights the potential for the use of ReNeuron's proprietary conditionally immortalised iPSCs in the treatment of peripheral nerve damage repair and the development of "off the shelf" stem cell-based therapies. Additionally, our CI-iPSCs are a key enabling technology for the expansion of the Company's CustomExTM exosome platform that allows growth beyond ReNeuron's current seven distinct exosome producing stem cell lines, therefore offering further ability to customise the exosome cell type for partners' needs and the payload / target cell of their choice."
CustomExTM is a register trademark of ReNeuron Limited
ENDS
Contacts:
ReNeuron | www.reneuron.com/investors |
Catherine Isted, Chief Executive Officer | Via Walbrook PR |
John Hawkins, Chief Financial Officer |
|
|
|
Walbrook PR (Media & Investor Relations) | +44 (0)20 7933 8780 or reneuron@walbrookpr.com |
Alice Woodings / Paul McManus | +44 (0)7407 804 654 / +44 (0)7980 541 893 |
About ReNeuron
ReNeuron is a UK based Proprietary Stem Cell derived Exosome Technologies company, harnessing its unique stem cell technologies to develop 'off the shelf' treatments for diseases with significant unmet needs.
ReNeuron's stem cell derived proprietary Exosome Technology platform offers a delivery mechanism for a variety of payloads such as siRNA, mRNA, proteins, small molecules and genes. The Company has a growing number of partner collaborations with Global Pharma, Biotech and academic partners in this fast-expanding area of scientific and commercial interest. ReNeuron also has the ability, through its conditionally immortalised induced pluripotent stem cell (iPSC) platform, to make allogeneic tissue cells of choice and has the potential to produce exosomes with tissue specific targeting ability.
The Company has out-licenced its CTX Programme for stroke disability and hRPC programme in retinitis pigmentosa to Fosun in China and is looking to out-licence both these programmes in other territories.
ReNeuron's shares are traded on the London AIM market under the symbol RENE.L. For further information visit www.reneuron.com